NDC 50090-5626-01 - Losartan Potassium

This NDC is not currently matched to an FDA NDC product listing in FDA.report, but it is a valid NDC-form code. FDA.report is showing the available DailyMed label context for the product root.

Product NDC
50090-5626
Requested NDC
50090-5626-01
Package NDCs from labels
50090-5626-0, 50090-5626-2, 50090-5626-1, 50090-5626-01
Manufacturer
A-S Medication Solutions
Effective date
2026-09-21
Current FDA listing
Not matched in FDA.report NDC product tables

DailyMed Labels#

Label, Manufacturer, Effective date table
LabelManufacturerEffective dateType
Losartan Potassium - A-S Medication SolutionsA-S Medication Solutions2026-09-21HUMAN PRESCRIPTION DRUG LABEL

FDA-Initiated Inactive NDC Indexing#

NDC, Effective, Related label table
NDCEffectiveRelated label
50090-5626-02023-02-06These highlights do not include all the information needed to use LOSARTAN POTASSIUM TABLETS USP safely and effectively. See full prescribing information for LOSARTAN POTASSIUM TABLETS USP. LOSARTAN POTASSIUM tablets USP, for oral use Initial U.S. Approval: 1995
50090-5626-02023-02-06These highlights do not include all the information needed to use LOSARTAN POTASSIUM TABLETS safely and effectively. See full prescribing information for LOSARTAN POTASSIUM TABLETS. LOSARTAN POTASSIUM tablets, for oral use Initial U.S. Approval: 1995
50090-5626-12023-02-06These highlights do not include all the information needed to use LOSARTAN POTASSIUM TABLETS USP safely and effectively. See full prescribing information for LOSARTAN POTASSIUM TABLETS USP. LOSARTAN POTASSIUM tablets USP, for oral use Initial U.S. Approval: 1995
50090-5626-12023-02-06These highlights do not include all the information needed to use LOSARTAN POTASSIUM TABLETS safely and effectively. See full prescribing information for LOSARTAN POTASSIUM TABLETS. LOSARTAN POTASSIUM tablets, for oral use Initial U.S. Approval: 1995
50090-5626-02023-01-30These highlights do not include all the information needed to use LOSARTAN POTASSIUM TABLETS USP safely and effectively. See full prescribing information for LOSARTAN POTASSIUM TABLETS USP. LOSARTAN POTASSIUM tablets USP, for oral use Initial U.S. Approval: 1995
50090-5626-02023-01-30These highlights do not include all the information needed to use LOSARTAN POTASSIUM TABLETS safely and effectively. See full prescribing information for LOSARTAN POTASSIUM TABLETS. LOSARTAN POTASSIUM tablets, for oral use Initial U.S. Approval: 1995
50090-5626-12023-01-30These highlights do not include all the information needed to use LOSARTAN POTASSIUM TABLETS USP safely and effectively. See full prescribing information for LOSARTAN POTASSIUM TABLETS USP. LOSARTAN POTASSIUM tablets USP, for oral use Initial U.S. Approval: 1995
50090-5626-12023-01-30These highlights do not include all the information needed to use LOSARTAN POTASSIUM TABLETS safely and effectively. See full prescribing information for LOSARTAN POTASSIUM TABLETS. LOSARTAN POTASSIUM tablets, for oral use Initial U.S. Approval: 1995

DailyMed Package Descriptions#

Package NDC, Product, Description table
Package NDCProductDescriptionFormQuantityStrengthSPL version
50090-5626-0Losartan Potassium30 in 1 BOTTLETABLET307
50090-5626-1Losartan Potassium90 in 1 BOTTLETABLET907
50090-5626-2Losartan Potassium100 in 1 BOTTLETABLET1007

DailyMed Dashboard NDC Coverage#

NDC, Dashboard title, SPL version table
NDCDashboard titleSPL versionValidationDashboard ZIP
50090-5626LOSARTAN POTASSIUM TABLET [A-S MEDICATION SOLUTIONS]7Current NDC, Legacy NDC, 3 package rows20241017_7a945396-dd71-4b16-bfab-947982407f36.zip

DailyMed Billing Units#

Package NDC, Billing unit, Product NDC table
Package NDCBilling unitProduct NDCDailyMed indexing SPLSPL versionEffective
50090-5626-0EA - Each50090-56268af4d83c-721b-4bd5-bd41-2a5f6c3b805b12022-06-06
50090-5626-1EA - Each50090-5626498dd9f8-127e-4f2c-81f8-101c4b1934d712022-06-06
50090-5626-2EA - Each50090-5626183fc350-4cb3-4ced-a1d9-de7208ef891a12023-04-07

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 2 of 145 · 2,882 matching rows.

Brand, Generic, Manufacturer table
BrandGenericManufacturerSPL set IDEffective dateAvailable safety fieldsJoin
HERA SILKYSTAY FOUNDATION 45N1TITANIUM DIOXIDEAmorepacific Corporation5f4326fc-b3c3-1a8b-e063-6294a90a8d9b2026-11-01WarningsExact identifier
unii: 15FIX9V2JP
HERA SILKYSTAY FOUNDATION 45W1TITANIUM DIOXIDEAmorepacific Corporation5f4335c8-596f-3269-e063-6294a90a6c3d2026-11-01WarningsExact identifier
unii: 15FIX9V2JP
HERA SILKYSTAY FOUNDATION 46W1TITANIUM DIOXIDEAmorepacific Corporation5f43404e-bdab-3f4b-e063-6294a90ab8812026-11-01WarningsExact identifier
unii: 15FIX9V2JP
HERA SILKYSTAY FOUNDATION 47N1TITANIUM DIOXIDEAmorepacific Corporation5f435148-dcb1-cfdf-e063-6394a90aa8b62026-11-01WarningsExact identifier
unii: 15FIX9V2JP
HERA SILKYSTAY FOUNDATION 50N1TITANIUM DIOXIDEAmorepacific Corporation5f43610f-6c4f-dd9d-e063-6394a90ab60a2026-11-01WarningsExact identifier
unii: 15FIX9V2JP
HERA SILKYSTAY FOUNDATION 48N1TITANIUM DIOXIDEAmorepacific Corporation5f4372c4-b87a-91ab-e063-6294a90a68072026-11-01WarningsExact identifier
unii: 15FIX9V2JP
HERA SILKYSTAY FOUNDATION 49C1TITANIUM DIOXIDEAmorepacific Corporation5f4380d1-2cf4-1fd8-e063-6394a90a0aa32026-11-01WarningsExact identifier
unii: 15FIX9V2JP
HERA BLACK CUSHION FOUNDATION 13N1OCTINOXATE, TITANIUM DIOXIDE, AND ZINC OXIDEAmorepacific Corporation5aff3d25-d034-0815-e063-6294a90a86642026-10-29WarningsExact identifier
unii: 15FIX9V2JP
Blue Lizard Sensitive SPF 50 SunscreenTITANIUM DIOXIDE AND ZINC OXIDECrown Laboratories32d78048-d281-1d80-e063-6394a90aec192026-10-28WarningsExact identifier
unii: 15FIX9V2JP
HERA SILKYSTAY FOUNDATION 32W1TITANIUM DIOXIDEAmorepacific Corporation5eed2165-afc2-6958-e063-6294a90add582026-10-28WarningsExact identifier
unii: 15FIX9V2JP
HERA SILKYSTAY FOUNDATION 34O1TITANIUM DIOXIDEAmorepacific Corporation5eedd87b-a7b1-1abc-e063-6294a90ae29e2026-10-28WarningsExact identifier
unii: 15FIX9V2JP
HERA SILKYSTAY FOUNDATION 26N1TITANIUM DIOXIDEAmorepacific Corporation5ec7151e-4f83-4aca-e063-6294a90a98182026-10-26WarningsExact identifier
unii: 15FIX9V2JP
HERA SILKYSTAY FOUNDATION 26W1TITANIUM DIOXIDEAmorepacific Corporation5ec7276d-fcaf-65b2-e063-6394a90ac2202026-10-26WarningsExact identifier
unii: 15FIX9V2JP
HERA SILKYSTAY FOUNDATION 28C1TITANIUM DIOXIDEAmorepacific Corporation5ec73566-5d67-7153-e063-6394a90aba332026-10-26WarningsExact identifier
unii: 15FIX9V2JP
HERA SILKYSTAY FOUNDATION 28N1TITANIUM DIOXIDEAmorepacific Corporation5ec75100-153c-80cd-e063-6294a90a6d512026-10-26WarningsExact identifier
unii: 15FIX9V2JP
HERA SILKYSTAY FOUNDATION 28O1TITANIUM DIOXIDEAmorepacific Corporation5ec77f7a-4621-ac0c-e063-6294a90a3f702026-10-26WarningsExact identifier
unii: 15FIX9V2JP
HERA SILKYSTAY FOUNDATION 29N1TITANIUM DIOXIDEAmorepacific Corporation5ec7ab15-9cc1-d53a-e063-6294a90a41112026-10-26WarningsExact identifier
unii: 15FIX9V2JP
HERA SILKYSTAY FOUNDATION 29W1TITANIUM DIOXIDEAmorepacific Corporation5ec83b87-08bc-7590-e063-6294a90a0b782026-10-26WarningsExact identifier
unii: 15FIX9V2JP
HERA SILKYSTAY FOUNDATION 31C1TITANIUM DIOXIDEAmorepacific Corporation5ec857a3-7fd1-6461-e063-6394a90aacd72026-10-26WarningsExact identifier
unii: 15FIX9V2JP
HERA SILKYSTAY FOUNDATION 31N1TITANIUM DIOXIDEAmorepacific Corporation5ec871dc-f74e-765c-e063-6394a90a27a52026-10-26WarningsExact identifier
unii: 15FIX9V2JP

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.